West Pharmaceutical tops Q3 net sales, profit expectations, raises FY guidance

Overview

• US injectable solutions provider's Q3 net sales rose 8.7%, beating analyst expectations

• Adjusted EPS increased 35.7%, beating analyst expectations

• Company repurchased $231 mln of stock in Q3

Outlook

• West Pharmaceutical raises 2026 net sales guidance to $3.41 bln-$3.42 bln

• Company lifts 2026 adjusted-diluted EPS forecast to $9.38-$9.48

• Company now expects 2026 organic net sales growth of 11.3%-11.6%

Result Drivers

• HVP COMPONENTS - Co said growth was led by High-Value Product Components business

• SALES PERFORMANCE - Co attributed operating income margin expansion and EPS growth to robust sales performance

• PROPRIETARY PRODUCTS - Co said Proprietary Products segment drove net sales growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for West Pharmaceutical Services, Inc. is $410.00, about 1.6% above its October 28 closing price of $403.64

• The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 40 three months ago

Reuters Recommended Reads

• Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

• Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook

• Oct 28 - Conmed Q3 adjusted EPS beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)